Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 12 January 2018
Indication(s)
IXIARO is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged 2 months and older.
IXIARO should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Chronic Spontaneous Urticaria (CSU)
Use our patient case studies to discover how experts diagnose and treat chronic spontaneous urticaria.
+ 7 more
Allergic Rhinitis
Allergic rhinitis causes great strain on the workforce. Help to reduce sick days and improve productivity with appropriate treatment options.
+ 4 more
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Atopic Dermatitis
The Atopic Dermatitis Knowledge Centre is an educational resource, intended for healthcare professionals, that provides credible medical information on the epidemiology, pathophysiology and burden of atopic dermatitis, as well as diagnostic techniques, treatment regimens and guideline recommendations.
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Related Content
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate...
Added 3 years ago
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
The purpose of this study is to conduct a passive surveillance of hospitalized dengue cases in subjects who participated in...
Added 5 years ago
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
The aim of this trial is to assess the efficacy of the CYD dengue vaccine in preventing symptomatic, virologically-confirmed dengue...
Added 8 years ago
Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America
The aim of the study is to assess the efficacy of sanofi pasteur's CYD dengue vaccine in preventing symptomatic virologically-confirmed...
Added 8 years ago
A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years
The proposed study is aimed at assessing the safety and immunogenicity of rMenB+OMV NZ when administered alone without routine infant...
Added 8 years ago
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Neisseria meningitidis is a common cause of bacterial meningitis, often leading to permanent sequelae or death. N. meningitidis is classified into serogroups based on the composition of the bacterial capsular polysaccharide...
Added 1 year ago
The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease.
Trumenba (bivalent rLP2086) is a vaccine licensed for the prevention of meningococcal meningitis disease caused by Neisseria meningitidis serogroup B (NmB) in individuals 10-25 years of age in the USA.
Added 1 year ago
Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba®): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review.
Background: In February 2015, two unlinked culture-confirmed cases of Neisseria meningitidis serogroup B (MenB) disease occurred at a local college in Rhode Island ("college X") within 3 days.
Added 1 year ago
Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
Background: The duration of protection in children and adults resulting from hepatitis B vaccination is unknown. In 1981, we immunized...
Added 3 years ago
Management of suspected viral encephalitis in children
The scope of the guideline is to cover the initial management of all patients with suspected encephalitis, up to the point of diagnosis and early treatment, in an acute care setting such as acute medical unit or emergency room.
Added 7 years ago
Chickenpox in Pregnancy
Varicella, the primary infection with varicella-zoster virus (VZV; human herpesvirus 3), in pregnancy may cause maternal mortality or serious morbidity. It may also cause fetal varicella syndrome (FVS) and varicella infection of the newborn...
Added 4 years ago
The Prevention of Early-onset Neonatal Group B Streptococcal Disease
The purpose of this guideline is to provide guidance for obstetricians, midwives and neonatologists on the prevention of early-onset (less than 7 days of age) neonatal group B streptococcal (EOGBS) disease...
Added 6 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/000963 |
Orphan designation | No |
Date First Approved | 31-03-2009 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Valneva Austria GmbH |